

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/634,713
Filing Date	August 5, 2004
First Named Inventor	Joseph Picard
Art Unit	1624
Examiner Name	Rao, Deepak R.
Attorney Docket Number	PC25298A

Total Number of Pages in This Submission

**ENCLOSURES (Check all that apply)**

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to a Technology Center (TC)<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br>Statement as Provided by 37 CFR 1.97 (2pgs), Required Copies of Art and Return Postcard |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Remarks**

AUTHORIZATION TO CHARGE A FEE AND ANY ADDITIONAL FEES AS NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 23-0455 IS HEREBY GIVEN.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**


Firm or Individual	Claude F. Purchase, Jr
Signature	<i>Claude F. Purchase, Jr</i>
Date	June 28, 2005

**CERTIFICATE OF TRANSMISSION/MAILING**I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date 6/28/05

Typed or printed	Cynthia D. Bernges		
Signature	<i>Cynthia D. Bernges</i>	Date	6/28/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PC 25298A

**UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/634,713

Confirmation No.: 8924

Applicant: Joseph Picard

Filed: August 5, 2003

TC/A.U.: 1624

Examiner: Deepak R. Rao

Docket No.: PC 25298A

Customer No.: 28880

Title: "Monocyclic derivatives as matrix metalloproteinase inhibitors"

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**(37 C.F.R. §1.97)**

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form PTO/SB/08a and PTO/SB/08b are brought to the attention of the Examiner.

Applicants believe that the Supplemental Information Disclosure Statement submitted herewith is being filed before the first Office Action on the merits

No representation is made hereby that a reference is "prior art" within the meaning of 35 U.S.C. §§102 or 103.

Consideration of the items listed is respectfully requested in accordance with 37 CFR § 1.104(a). Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Forms PTO/SB/08a and PTO/SB/08b, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

It is respectfully requested that all cited references considered by the Examiner be listed in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully Submitted,

Dated: June 28, 2005

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.  
Registration No. 47,871  
Warner -Lambert Company  
2800 Plymouth Road  
Ann Arbor, Michigan 48105  
Telephone: (734) 622-1692  
Facsimile: (734) 622-1553

A circular stamp from the Patent &amp; Trademark Office. The text "OIP EJC10" is curved along the top inner edge. The date "JUL 05 2005" is stamped in the center. The text "PATENT &amp; TRADEMARK OFFICE" is curved along the bottom inner edge. A portion of the word "Custom" is visible at the top right.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

*(Use as many sheets as necessary)*

Sheet	1	of	4
-------	---	----	---

Application Number	10/634,713
Filing Date	August 5, 2003
First Named Inventor	Joseph Picard
Art Unit	1624
Examiner Name	Rao, Deepak R.
Attorney Docket Number	PC 25298A

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> ~Number <sup>4</sup> ~Kind Code <sup>5</sup> (if known)				
		WO 01/63244 A1	8/30/2001	Chen, et al.		
		WO 00/09485 A1	2/24/2000	McClure, et al.		
		WO 01/12611 A1	2/22/2001	Blagg, Julian		
		WO 02/34726 A2	5/2/2002	Noe, et al.		
		WO 02/34753 A2	5/2/2002	Bronk, et al.		
		EP 0935963 A2	8/18/1999	McClure, et al		

Date  
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***

**Complete if Known**

***(Use as many sheets as necessary)***

2

of

4

Application Number	10/634,713
Filing Date	August 5, 2003
First Named Inventor	Joseph Picard
Art Unit	1624
Examiner Name	Rao, Deepak R.
Attorney Docket Number	PC 25298A

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> ~Number <sup>4</sup> ~Kind Code <sup>5</sup> (if known)				
		EP 1138680 A1	10/4/2001	Noe, Mark Carl		
		CA 2,082,076	05/06/1993	Weidmann et al.		
		WO 00/44730	8/3/2000	Albright, et al.		
		WO 02/64568	8/22/2002	Barvian, et al.		
		WO 02/64578	8/22/2002	Picard, et al.		

Date  
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/634,713
				Filing Date	August 5, 2003
				First Named Inventor	Joseph Picard
				Art Unit	1624
				Examiner Name	Rao, Deepak R.
Sheet	3	of	4	Attorney Docket Number	PC 25298A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
		CHEN, et al., Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design, J. Am. Chem. Soc., 2000, pp. 9648-9654, vol. 122		
		LOVEJOY, et al., Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors, Nature Structural Biology, 1999, pp. 217-221, vol. 6(3)		
		MOY, et al., High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with Hydroxamic Acid Inhibitor, J. Mol. Biol., 2000, pp. 671-689, vol. 302		
		MITCHELL, et al., Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage, J. Clin. Invest., 1996, pp. 761-768, vol. 97(3)		
		NEUHOLD, et al, Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) incuces osteoarthritis in mice, J. Clin. Invest., 2001, pp 35-44, vol. 107 (1)		
		DAHLBERG, et al, Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase 1), Arthritis & Rheumatism, 2000, pp. 673-682, vol., 43(3)		
		BILLINGHURST, et al., Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase, Arthritis & Rheumatism, 2000, pp. 664-672, vol, 43(3)		
		BILLINGHURST, et al, Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage, J. Clin. Invest., 1997, pp. 1534-1545, vol. 99(7)		
		HIROTA, et al., Novel Synthesis of Pyrido[3,4-d]Pyrimidines, Pyrido[2,3-d]Pyrimidines, and Quinazolines Via Palladium-Catalyzed Oxidative Coupling, Heterocycles, 1994, pp 563-570, vol. 37(1)		
		WERNICKE, et al., Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatoid Arthritis and Osteoarthritis, J. Rheum, 1996, pp 590-595, vol. 23(4)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/634,713
				Filing Date	August 5, 2003
				First Named Inventor	Joseph Picard
				Art Unit	1624
				Examiner Name	Rao, Deepak R.
Sheet	4	of	4	Attorney Docket Number	PC 25298A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		REBOUL, et al, The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes, J. Clin. Invest., 1996, pp. 2011-2019, vol. 97(9)	
		FREEMONT, et al., In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage, Am Rheum Dis, 1999, pp. 357-365, vol. 58	
		Office Action mailed June 16, 2003, in U.S. Application No. 10/264,764 (19 Pages)	
		Search Report from International Application No. PCT/IB03/03613	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.